Johnson & Johnson is trading 3.1% down at €228.05, with no confirmed cause for the decline.
- On October 13, the company reported third-quarter adjusted EPS of $2.59 and sales of $25.4 billion, and raised 2026 guidance.
- The release does not report a stock reaction; earnings were published after the supplied October 12 session close.
- Available price context identifies a significant decline, but no confirmed market close for October 13.